Contrasting Haleon (NYSE:HLN) and Bio-Rad Laboratories (NYSE:BIO)

Haleon (NYSE:HLN) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Haleon and Bio-Rad Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haleon	1	2	4	2	2.78
Bio-Rad Laboratories	1	3	2	0	2.17

Haleon currently has a consensus price target of $12.33, suggesting a potential upside of 23.56%. Bio-Rad Laboratories has a consensus price target of $339.75, suggesting a potential upside of 20.83%. Given Haleon’s stronger consensus rating and higher possible upside, research analysts clearly believe Haleon is more favorable than Bio-Rad Laboratories.

Profitability

This table compares Haleon and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haleon	N/A	N/A	N/A
Bio-Rad Laboratories	29.42%	3.86%	2.70%

Risk and Volatility

Haleon has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

Insider and Institutional Ownership

6.7% of Haleon shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 17.1% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Haleon and Bio-Rad Laboratories”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haleon	$14.54 billion	3.05	$2.20 billion	$0.39	25.58
Bio-Rad Laboratories	$2.58 billion	2.94	$759.90 million	$27.91	10.07

Haleon has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Summary

Haleon beats Bio-Rad Laboratories on 8 of the 15 factors compared between the two stocks.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.